FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329	
OIPE AND INFORMATION DISCLOSURE APR O & MARIE STATEMENT BY APPLICANT	APPLICANT Bondarev		
(37 CFR 1.98(b))	FILING DATE January 15, 2004	GROUP 1635	

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
LW	AA	5,539,082	7/23/1996	Nielsen et al.		
	AB	5,714,331	2/3/1998	Buchardt et al.		
	AC	5,719,262	2/17/1998	Buchardt et al.		
	AD	6,046,307	4/4/2000	Shay et al.		
	AE	6,194,206	02/27/2001	West et al.		
	AF	6,156,763	12/05/2000	Kerwin et al.		
	AG	6,294,332	9/25/2001	Chabot		

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BA					
	BB					
	BC					

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
LW	CA	De Clercq, "Recent developments in the chemotherapy of HIV infections", Pure & Appl. Chem., Vol. 70, No. 3, pp. 567-577, 1998.
LW	СВ	Yamaguchi, et al., "Telomerase-inhibitory effects of the triphosphate derivatives of some biologically active nucleosides", Nucleic Acids Research Supplement No. 1, pp. 211-212, 2001.
LW	СС	Bisoffi, et al., "Inhibition of Human Telomerase by a Retrovirus Expressing Telomeric Antisense RNA", European Journal of Cancer, Vol. 34, No. 8, pp. 1242-1249, 1998.
LW	CD	Roth, et al., "Telomerase is limiting the growth of acute myeloid leukemia cells", Leukemia, 17, pp. 2410-2417, 2003.
LW	CE	Damm, et al., "A highly selective telomerase inhibitor limiting human cancer cell proliferation", The EMBO Journal, Vol. 20., No. 24, pp. 6958-6968, 2001.
LW	CF	GeneBank GI:5070620, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=5070620. 8/26/05

EXAMINER	/Louis Wollenberger/	DATE CONSIDERED
		05/25/2006

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Bondarev	
STATEMENT BY AFFEIGANT	FILING DATE	GROUP
(37 CFR 1.98(b))	January 15, 2004	1635

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
LW	AH	6,723,712	4/20/2004	Bourhis et al.		
	Al					
	AJ					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BD					
	BE					
	BF					

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
LW	CG	Kimberland, et al., "Full-length human L 1 insertions retain the capacity for high frequency retrotransposition in cultured cells", Human Molecular Genetics, 1999, Vol. 8, No. 8, pp. 1557-1560.
LW	СН	Dorafshar, et al., "Vascular Endothelial Growth Factor Inhibits Mitogen-Induced Vascular Smooth Muscle Cell Proliferation", Journal of Surgical Research, 114, pp. 179-186, 2003.
LW	СІ	Yang, et al., "Effects of GM-CSF, IL-3, and GM-CSF/ IL-3 fusion protein on apoptosis of human myeloid leukemic cell line Tf-1 induced by irraditiation", Acta Pharmacol Sin 2004 Jan; 25 (1): 68-75.
LW	Cl	Schwahn, et al., "Positional cloning of the gene for X-linked retinitis pigmentosa 2", Nature Genetics, Vol. 19, August 1998, pp. 327-332.
LW	СК	Holmes, et al., "A new retrotransposable human L1 element from the LRE2 locus on chromosome 1q produces a chimaeric insertion", Nature Genetics, Vol. 7, June 1994.

EXAMINER	/Louis Wollenberger/	DATE CONSIDERED
		05/25/2006

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Bondarev		
(37 CFR 1.98(b))	FILING DATE January 15, 2004	GROUP 1635	

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AK					
	AL					
	AM					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BG					
	ВН					
	BI					

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Exami Initia		Cite No.	
LW CL		CL	Yoshida, et al., "Insertional mutation by transposable element, L1, in the DMD gene results in X-linked dilated cardiomyopathy", Human Molecular Genetics, 1998, Vol. 7, No. 7, pp. 1129-1132.
	T	СМ	Brouha, et al., "Evidence Consistent with Human L1 Retrotransposition in Maternal Meiosis I, Am J. Hum. Genet. Vol. 71, pp. 327-336, 2002.
		CN	Atlschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Research, Vol. 25, No. 17 pp. 3389-3402, 1997.
		со	Ahlquist, "RNA-Dependant RNA Polymerases, Viruses, and RNA Silencing", Science, Vol. 296 pp. 1270-1273, May 17, 2002.
		СР	Yeager, et al., "Telomerase-negative Immortalized Human Cells Contain a Novel Type of Promyelocytic Leukemia (PML) Body" Cancer Research, Vol. 59, pp. 4175-4179, September 1, 1999.
V	,	CQ	Rudolph, et al., "Longevity, Stress Response, and Cancer in Aging Telomerase-Deficient Mice", Cell, Vol. 96, pp. 710-712, March 5, 1999.

EXAMINER	/Louis Wollenberger/	DATE CONSIDERED
		05/25/2006

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Bondarev		
	FILING DATE	GROUP	
(37 CFR 1.98(b))	January 15, 2004	1635	

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AN					
	AO					
	AP					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BJ					
	BK				,`	
	BL					

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

		Cite No.	
I.	LW		Wang, et al., "Prolonged and Inducible Transgene Expression in the Liver Using Gutless Adenovirus: A Potential Therapy for Liver Cancer", Gastroenterology, Vol. 126, pp. 278-289, 2004.
	7	CS	Bryan, et al., "Telomere Dynamics and Telomerase Activity In <i>In Vitro</i> Immortalised Human Cells, European Journal of Cancer, Vol. 33, No. 5, pp. 767-773, 1997.
	1	СТ	Greider, et al., "Identification of a Specific Telomere Terminal Transferase Activity in Tetrahymena Extracts", Cell, Vol. 43, pp. 405-413, December 1985, (Part 1).
	1	CU	Kim, et al., "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer", Science, Vol. 266, pp. 2011-2015, December 23, 1994.
		cv	Bryan, et al., "Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines", Nature Medicine, Vol. 3, No. 11, pp. 1271-1274, November 1997.
V	/	cw	Kazazian, Jr., et al., "The impact of L1 retrotransposons on the human genome", Nature Genetics, Vol. 19, pp. 19-24, May 1998.

EXAMINER	/Louis Wollenberger/	DATE CONSIDERED
		05/25/2006

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Bondarev		
(37 CFR 1.98(b))	FILING DATE January 15, 2004	GROUP 1635	

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AQ					
	AR					
	AS					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	ВМ					
	BN					
	во]	

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Cite Initial No.			
ΓM	LW		Nozawa, et al., "In vitro expansion of mammalian telomere repeats by DNA polymerase α-primase", Nucleic Acids Research, Vol. 28, No. 16, pp. 3117-3124, 2000.
	1	CY	Allshire, et al., "Human telomeres contain at least three types of G-rich repeat distributed non-randomly", Nucleic Acids Research, Vol. 17, No. 12, pp. 4611-4627, 1989.
	T	CZ	Hahn, et al., "Inhibition of telomerase limits the growth of human cancer cells", Nature Medicine, Vol. 5, No. 10, pp. 1164-1170, October 1999.
	T	CCA	Bryan, et al., "Telomere elongation in immortal human cells without detectable telomerase activity", The EMBO Journal, Vol. 14, No. 17, pp. 4240-4248, 1995.
		ССВ	Gupta, et al., "Development of Retinoblastoma in the Absence of Telomerase Activity", Journal of the National Cancer Institute, Vol. 88, No. 16, August 21, 1996.
V	/	ccc	Dunham, et al., "Telomere maintenance by recombination in human cells", Nature Genetics, Vol. 26, pp. 447-450, December 2000.

/	DATE CONSIDERED
/ Hould wollemergel/	05/25/2006

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Bondarev	
(37 CFR 1.98(b))	FILING DATE January 15, 2004	GROUP 1635

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AT					
	AU					
	AV					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BP					
	BQ					
	BR					

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

	Examiner		
Initi	al	No.	
LW		CCD	Clements, et al., "The human LINE-1 reverse transcriptase: effect of deletions outside the common reverse transcriptase domain", Nucleic Acids Research, Vol. 26, No. 15, pp. 3528-3535, 1998.
		CCE	Skowronski et al., "Expression of a cytoplasmic LINE-1 transcript is regulated in a human teratocarcinoma cell line", Proc. Natl. Acad. Sci. USA, Vol. 82, pp. 6050-6054, September 1985.
		CCF	Moran et al., "High Frequency Retrotransposition in Cultured Mammalian Cells", Cell, Vol. 87, pp. 917-927, November 29, 1996.
		CCG	Murakami, et al., "Inhibition of Telomerase Activity and Cell Proliferation by a Reverse Transcriptase Inhibitor in Gynaecological Cancer Cell Lines, European Journal of Cancer, Vol. 35, No. 6, pp. 1027-1034, 1999.
		ССН	Rufer, et al., "Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry", Nature Biotechnology, Vol. 16, p. 743-747, August 1998.
V		CCI	Hultdin, et al., "Telomere analysis by fluorescence in situ hybridization and flow cytometry", Nucleic Acids Research, Vol. 26, No. 16, pp. 3651-3656, 1998.

EXAMINER /Louis Wollenberger/		DATE CONSIDERED
		05/25/2006

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329
	APPLICANT	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Bondarev	
	FILING DATE	GROUP
	January 15, 2004	1635
(37 CFR 1.98(b))		

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AW					_
	AX					
	AY			·····		

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BS					<u> </u>
	ВТ					
	BU					

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner . Initial		al No.				
IW		CCJ	Perrem, et al. "Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids", Oncogene, Vol. 18, pp. 3383-3390, 1999.			
			Guiducci, et al., "Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability", Oncogene, Vol. 20, pp. 714-725, 2001.			
		CCL	Craig, et al., "Effects of adenovirus-mediated p16 ^{INK4A} expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells", Oncogene, Vol. 16, pp. 265-272, 1998.			
			Ostertag, et al., "Determination of L 1 retrotransposition kinetics in cultured cells", Nucleic Acids Research, Vol. 28, No. 6, pp. 1418-1423, 2000.			
V		CCN	Kuo, et al., "Expression of Transposon LINE-1 is Relatively Human-Specific and Function of the Transcripts May Be Proliferation-Essential, Biochemical and Biophysical Research Communications, 253, pp. 566-570 (1998).			

EXAMINER /Louis Wollenberger/		DATE CONSIDERED
		05/25/2006

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 04-40018-US	SER. NO. 10/758,329
N.F.O.D. I. T. I. D. I. O. I. D. I.	APPLICANT	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Bondarev	
	FILING DATE	GROUP
	January 15, 2004	1635
(37 CFR 1.98(b))		

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AW					
	AX					
	AY	1				

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
Γ		BS					

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Exan		r Cite No.	
rm / ccc		CCO	Hernandez, et al., "Systemic treatment modalities in the management of AIDS-related Kaposi's sarcoma", Journal of the European Academy of the Dermatology and Venereology, 9, 1997, pp. 44-49.
	CCP		Poirier, et al., "Perinatal genotoxicity and carcinogencity of anti-retroviral nucleoside analog drugs", Toxicology and Applied Pharmacology, 199, 2004, pp. 151-161.
	-11		Langford, et al., "Regression of oral Kaposi's sarcoma in a case of AIDS on Zidovudine (AZT), British Journal of Dermatology, vol. 120, 1989, pp. 709-713.
		CCR	Ofelia, et al., "Transplacental Effects of 3'-Azido-2', 3'-Dideoxythymidine (AZT): Tumorigenicity in Mice and Genotoxicity in Mice and Monkeys", Journal of the National Cancer Institute, Vol. 89, No. 21, November 5, 1997, pp. 1602-1618.
V	/	ccs	Pluda, et al., "Parameters Affecting the Development of Non-Hodgkin's Lymphoma in Patients With Severe Human Immunodeficiency Virus Infection Receiving Antiretroviral Therapy", Journal of Clinical Oncology, Vol. 11, No. 6, June 1993, pp. 1099-1107.

EXAMINER	DATE CONSIDERED
/Louis Wollenberger/	05/25/2006

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 04-40018-US SER. NO. 10/758,329		
INFORMATION DISCLOSURE WAY 22 1006 PATEMENT BY APPLICANT	APPLICANT Bondarev		
(37 CFR 1.98(b))	FILING DATE January 15, 2004	GROUP 1635	

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BA					
	BB					
	ВС					

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
LW	LW CA Giordano, et al., "Reverse Transcriptase Activity in Mature Spermatozoa of Mouse", The Jour Cell Biology, vol. 148, no. 6, March 20, 2000, pp. 1107-1113.	
LW Mangiacasale, et al., "Exposure of normal and transformed cells to nevirapine, a rever transcriptase inhibitor, reduces cell growth and promotes differentiation", Oncogene, v pp. 2750-2761.		Mangiacasale, et al., "Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation", Oncogene, vol. 22, 2003, pp. 2750-2761.
		Beraldi, et al, "Expression of LINE-1 Retroposons Is Essential for Murine Preimplantation Development", Molecular Reproduction and Development, vol. 73, 2006, pp. 279-287.
LW CD Soifer, et al., "A potential role for RNA interference in controlling the active retrotransposon", Nucleic Acids Research, vol. 33, no. 3, 2005, pp. 846-8		Soifer, et al., "A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon", Nucleic Acids Research, vol. 33, no. 3, 2005, pp. 846-856.
CE Sciamanna, et al., "Inhibition of endogenous revergrowth", Oncogne, vol. 24, 2005, pp. 3923-2931.		Sciamanna, et al., "Inhibition of endogenous reverse transcriptase antagonizes human tumor growth", Oncogne, vol. 24, 2005, pp. 3923-2931.

EXAMINER	DATE CONSIDERED
/Louis Wollenberger/	05/31/2006